1. From Phenylthiazoles to Phenylpyrazoles: Broadening the Antibacterial Spectrum toward Carbapenem-Resistant Bacteria.
- Author
-
Hammad A, Abutaleb NS, Elsebaei MM, Norvil AB, Alswah M, Ali AO, Abdel-Aleem JA, Alattar A, Bayoumi SA, Gowher H, Seleem MN, and Mayhoub AS
- Subjects
- Acinetobacter baumannii drug effects, Anti-Bacterial Agents chemical synthesis, Anti-Bacterial Agents chemistry, Biofilms drug effects, Dose-Response Relationship, Drug, Escherichia coli drug effects, Klebsiella pneumoniae drug effects, Methicillin-Resistant Staphylococcus aureus drug effects, Microbial Sensitivity Tests, Molecular Structure, Pyrazoles chemical synthesis, Pyrazoles chemistry, Structure-Activity Relationship, Thiazoles chemical synthesis, Thiazoles chemistry, Anti-Bacterial Agents pharmacology, Carbapenems pharmacology, Drug Resistance, Multiple, Bacterial drug effects, Pyrazoles pharmacology, Thiazoles pharmacology
- Abstract
The narrow antibacterial spectrum of phenylthiazole antibiotics was expanded by replacing central thiazole with a pyrazole ring while maintaining its other pharmacophoric features. The most promising derivative, compound 23 , was more potent than vancomycin against multidrug-resistant Gram-positive clinical isolates, including vancomycin- and linezolid-resistant methicillin-resistant Staphylococcus aureus ( MRSA), with a minimum inhibitory concentration (MIC) value as low as 0.5 μg/mL. Moreover, compound 23 was superior to imipenem and meropenem against highly pathogenic carbapenem-resistant strains, such as Acinetobacter baumannii , Klebsiella pneumoniae, and Escherichia coli . In addition to the notable biofilm inhibition activity, compound 23 outperformed both vancomycin and kanamycin in reducing the intracellular burden of both Gram-positive and Gram-negative pathogenic bacteria. Compound 23 cleared 90% of intracellular MRSA and 98% of Salmonella enteritidis at 2× the MIC. Moreover, preliminary pharmacokinetic investigations indicated that this class of novel antibacterial compounds is highly metabolically stable with a biological half-life of 10.5 h, suggesting a once-daily dosing regimen.
- Published
- 2019
- Full Text
- View/download PDF